How to Buy torntpharm Shares on Fincept?
You can buy Torrent Pharmaceuticals Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Torrent Pharmaceuticals Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Torntpharm, including updates on board meetings and corporate actions.
Torrent Pharmaceuticals Limited - https://www.torrentpharma.com
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
Torrent Pharmaceuticals Limited Share Price Today
3,360.00
OPEN
3,393.60
HIGH
3,333.05
LOW
3,358.25
CLOSE
512 K
VOLUME
116,547 Cr
Market Cap
403073
Average Volume
Healthcare
Sector
NSI
Exchange
Torrent Pharmaceuticals Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: TORNTPHARM Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Torrent Pharmaceuticals Limited |
TORNTPHARM |
INE685A01028 |
Dividend - Rs 6 Per Share |
21 Jun 2024 |
5 |
N/A |
Torrent Pharmaceuticals Limited |
TORNTPHARM |
INE685A01028 |
Interim Dividend - Rs 22 Per Share |
12 Feb 2024 |
5 |
N/A |
Torrent Pharmaceuticals Limited |
TORNTPHARM |
INE685A01028 |
Dividend - Rs 8 Per Share |
23 Jun 2023 |
5 |
N/A |
Torrent Pharmaceuticals Limited |
TORNTPHARM |
INE685A01028 |
Interim Dividend - Rs 14 Per Share |
03 Feb 2023 |
5 |
N/A |
Torrent Pharmaceuticals Limited |
TORNTPHARM |
INE685A01028 |
Bonus 1:1 |
08 Jul 2022 |
5 |
N/A |
NSE: TORNTPHARM Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
TORNTPHARM |
27 Dec 2024, 14:07:12 |
Trading Window-XBRL |
Pharmaceuticals |
TORNTPHARM |
27 Dec 2024, 14:02:37 |
Trading Window |
Pharmaceuticals |
TORNTPHARM |
26 Dec 2024, 20:04:56 |
Issue of Securities |
Pharmaceuticals |
TORNTPHARM |
19 Dec 2024, 17:25:26 |
Updates |
Pharmaceuticals |
TORNTPHARM |
09 Dec 2024, 14:48:28 |
Copy of Newspaper Publication |
Pharmaceuticals |
NSE: TORNTPHARM Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Torrent Pharmaceuticals Limited |
TORNTPHARM |
16 Oct 2024, 19:12:00 |
16 Oct 2024, 19:12:00 |
|
Torrent Pharmaceuticals Limited |
TORNTPHARM |
15 Jul 2024, 18:29:00 |
15 Jul 2024, 18:29:00 |
|
Torrent Pharmaceuticals Limited |
TORNTPHARM |
20 Apr 2024, 13:51:00 |
05 Feb 2025, 23:25:15 |
|
Torrent Pharmaceuticals Limited |
TORNTPHARM |
12 Jan 2024, 15:45:00 |
12 Jan 2024, 16:15:00 |
|
Torrent Pharmaceuticals Limited |
TORNTPHARM |
13 Oct 2023, 22:46:00 |
13 Oct 2023, 23:15:00 |
NSE: TORNTPHARM Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson & Executive Director-CEO-MD |
18 Sep 1963 |
20 Aug 1986 |
00061903 |
Samir Uttamlal Mehta |
- |
Independent Director |
24 Sep 1979 |
02 Aug 2018 |
00208095 |
Ameera Sushil Shah |
- |
Independent Director |
13 Jun 1966 |
07 Mar 2019 |
03570657 |
Nayantara Bali |
- |
Independent Director |
28 Mar 1961 |
11 May 2022 |
09592878 |
Maurice Chagnaud |
- |
Independent Director |
12 Sep 1967 |
29 Jul 2022 |
00026496 |
Manish Mahendra Choksi |
- |
NSE: TORNTPHARM Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
TORRENT PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 25-Oct-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2024 and Other business. |
TORNTPHARM |
N/A |
INE685A01028 |
Torrent Pharmaceuticals Limited |
10 Oct 2024, 14:45:44 |
Financial Results/Other business matters |
TORNTPHARM |
N/A |
INE685A01028 |
Torrent Pharmaceuticals Limited |
05 Jul 2024, 19:08:25 |
Financial Results/Dividend/Fund Raising |
TORNTPHARM |
N/A |
INE685A01028 |
Torrent Pharmaceuticals Limited |
10 May 2024, 18:05:55 |
Financial Results/Dividend/Other business matters |
TORNTPHARM |
N/A |
INE685A01028 |
Torrent Pharmaceuticals Limited |
12 Jan 2024, 10:41:02 |
TORRENT PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 23-Oct-2023 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2023 and Other business. |
TORNTPHARM |
N/A |
INE685A01028 |
Torrent Pharmaceuticals Limited |
09 Oct 2023, 18:50:03 |
NSE: TORNTPHARM Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results/Other business matters |
TORNTPHARM |
- |
INE685A01028 |
Torrent Pharmaceuticals Limited |
10 Oct 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 and other business matters |
Financial Results/Other business matters |
TORNTPHARM |
- |
INE685A01028 |
Torrent Pharmaceuticals Limited |
05 Jul 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 and other business matters |
Financial Results/Dividend/Fund Raising |
TORNTPHARM |
- |
INE685A01028 |
Torrent Pharmaceuticals Limited |
10 May 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024, dividend and Fund Raising |
Financial Results/Dividend/Other business matters |
TORNTPHARM |
- |
INE685A01028 |
Torrent Pharmaceuticals Limited |
12 Jan 2024, 00:00:00 |
To consider and approve the financial results for the period ended December 31, 2023, dividend and other business matters |
Financial Results |
TORNTPHARM |
- |
INE685A01028 |
Torrent Pharmaceuticals Limited |
09 Oct 2023, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2023 We would like to inform you that a meeting of the Board of Directors will be held on Monday, 23-Oct-23, inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-23. |
NSE: TORNTPHARM Balance Sheet Data In (Cr)
| date | period_type | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Other Non Current Liabilities | Derivative Product Liabilities | Tradeand Other Payables Non Current | Non Current Deferred Revenue | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Debt And Capital Lease Obligation | Current Capital Lease Obligation | Current Debt | Current Provisions | Payables | Other Payable | Dividends Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Non Current Deferred Taxes Assets | Financial Assets | Investmentin Financial Assets | Available For Sale Securities | Goodwill And Other Intangible Assets | Other Intangible Assets | Goodwill | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Hedging Assets Current | Assets Held For Sale Current | Restricted Cash | Prepaid Assets | Inventory | Other Inventories | Finished Goods | Work In Process | Raw Materials | Other Receivables | Taxes Receivable | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 338,445,440.00 | 338,445,440.00 | 19,020,000,000.00 | 31,260,000,000.00 | 28,310,000,000.00 | 105,520,000,000.00 | 10,320,000,000.00 | 28,310,000,000.00 | 780,000,000.00 | 75,040,000,000.00 | 89,180,000,000.00 | 75,040,000,000.00 | 0.00 | 75,040,000,000.00 | 73,350,000,000.00 | 0.00 | 0.00 | 1,690,000,000.00 | 1,690,000,000.00 | 75,840,000,000.00 | 27,370,000,000.00 | 10,000,000.00 | 0.00 | 0.00 | 0.00 | 7,930,000,000.00 | 14,740,000,000.00 | 600,000,000.00 | 14,140,000,000.00 | 4,460,000,000.00 | 48,470,000,000.00 | 1,770,000,000.00 | 16,520,000,000.00 | 180,000,000.00 | 16,340,000,000.00 | 4,350,000,000.00 | 22,790,000,000.00 | 0.00 | 0.00 | 910,000,000.00 | 21,880,000,000.00 | 150,880,000,000.00 | 92,090,000,000.00 | 330,000,000.00 | 0.00 | 5,810,000,000.00 | 0.00 | 650,000,000.00 | 650,000,000.00 | 46,730,000,000.00 | 43,340,000,000.00 | 3,390,000,000.00 | 36,290,000,000.00 | 0.00 | 36,290,000,000.00 | 4,120,000,000.00 | 32,170,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 58,790,000,000.00 | 3,380,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22,710,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40,000,000.00 | 0.00 | 17,830,000,000.00 | 0.00 | 0.00 | 14,830,000,000.00 | 3,370,000,000.00 | 11,460,000,000.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 338,445,440.00 | 338,445,440.00 | 31,022,800,000.00 | 40,219,400,000.00 | 19,353,000,000.00 | 107,935,700,000.00 | 1,862,300,000.00 | 19,353,000,000.00 | 845,200,000.00 | 68,561,500,000.00 | 84,599,300,000.00 | 68,561,500,000.00 | 0.00 | 68,561,500,000.00 | 66,870,000,000.00 | 39,424,000,000.00 | 714,300,000.00 | 1,692,300,000.00 | 1,692,300,000.00 | 82,044,300,000.00 | 27,791,800,000.00 | 10,000,000.00 | 2,400,000.00 | 0.00 | 9,600,000.00 | 6,560,500,000.00 | 16,682,400,000.00 | 644,600,000.00 | 16,037,800,000.00 | 4,446,900,000.00 | 54,252,500,000.00 | 1,300,000,000.00 | 23,537,000,000.00 | 200,600,000.00 | 23,336,400,000.00 | 4,001,400,000.00 | 26,281,100,000.00 | 3,670,000,000.00 | 38,600,000.00 | 1,679,300,000.00 | 20,893,200,000.00 | 150,605,800,000.00 | 94,491,000,000.00 | 150,000,000.00 | 380,400,000.00 | 5,551,300,000.00 | 43,800,000.00 | 332,900,000.00 | 332,900,000.00 | 49,208,500,000.00 | 45,828,200,000.00 | 3,380,300,000.00 | 35,777,700,000.00 | -20,315,800,000.00 | 56,093,500,000.00 | 2,808,000,000.00 | 2,846,100,000.00 | 26,530,600,000.00 | 16,111,300,000.00 | 7,797,500,000.00 | 0.00 | 56,114,800,000.00 | 3,040,000,000.00 | 251,600,000.00 | 0.00 | 38,600,000.00 | 1,130,900,000.00 | 22,790,700,000.00 | 610,500,000.00 | 14,339,500,000.00 | 1,409,500,000.00 | 6,431,200,000.00 | 2,469,300,000.00 | 950,700,000.00 | 18,443,000,000.00 | -112,100,000.00 | 18,555,100,000.00 | 10,040,000,000.00 | 1,688,600,000.00 | 8,351,400,000.00 | 3,992,900,000.00 | 4,358,500,000.00 |
| 2024-03-31T00:00:00 | annual | 338,445,440.00 | 338,445,440.00 | 31,022,800,000.00 | 40,219,400,000.00 | 19,353,000,000.00 | 107,935,700,000.00 | 1,862,300,000.00 | 19,353,000,000.00 | 845,200,000.00 | 68,561,500,000.00 | 84,599,300,000.00 | 68,561,500,000.00 | 0.00 | 68,561,500,000.00 | 66,870,000,000.00 | 39,424,000,000.00 | 714,300,000.00 | 1,692,300,000.00 | 1,692,300,000.00 | 82,044,300,000.00 | 27,791,800,000.00 | 10,000,000.00 | 2,400,000.00 | 0.00 | 9,600,000.00 | 6,560,500,000.00 | 16,682,400,000.00 | 644,600,000.00 | 16,037,800,000.00 | 4,446,900,000.00 | 54,252,500,000.00 | 1,300,000,000.00 | 23,537,000,000.00 | 200,600,000.00 | 23,336,400,000.00 | 4,001,400,000.00 | 26,281,100,000.00 | 3,670,000,000.00 | 38,600,000.00 | 1,679,300,000.00 | 20,893,200,000.00 | 150,605,800,000.00 | 94,491,000,000.00 | 150,000,000.00 | 380,400,000.00 | 5,551,300,000.00 | 43,800,000.00 | 332,900,000.00 | 332,900,000.00 | 49,208,500,000.00 | 45,828,200,000.00 | 3,380,300,000.00 | 35,777,700,000.00 | -20,315,800,000.00 | 56,093,500,000.00 | 2,808,000,000.00 | 2,846,100,000.00 | 26,530,600,000.00 | 16,111,300,000.00 | 7,797,500,000.00 | 0.00 | 56,114,800,000.00 | 3,040,000,000.00 | 251,600,000.00 | 0.00 | 38,600,000.00 | 1,130,900,000.00 | 22,790,700,000.00 | 610,500,000.00 | 14,339,500,000.00 | 1,409,500,000.00 | 6,431,200,000.00 | 2,469,300,000.00 | 950,700,000.00 | 18,443,000,000.00 | -112,100,000.00 | 18,555,100,000.00 | 10,040,000,000.00 | 1,688,600,000.00 | 8,351,400,000.00 | 3,992,900,000.00 | 4,358,500,000.00 |
| 2023-09-30T00:00:00 | quarterly | 338,445,440.00 | 338,445,440.00 | 38,780,000,000.00 | 44,890,000,000.00 | 15,300,000,000.00 | 111,230,000,000.00 | 3,740,000,000.00 | 15,300,000,000.00 | 730,000,000.00 | 67,070,000,000.00 | 88,170,000,000.00 | 67,070,000,000.00 | 0.00 | 67,070,000,000.00 | 65,380,000,000.00 | 0.00 | 0.00 | 1,690,000,000.00 | 1,690,000,000.00 | 80,370,000,000.00 | 31,390,000,000.00 | 10,000,000.00 | 0.00 | 0.00 | 0.00 | 5,600,000,000.00 | 21,610,000,000.00 | 510,000,000.00 | 21,100,000,000.00 | 4,080,000,000.00 | 48,980,000,000.00 | 1,230,000,000.00 | 23,280,000,000.00 | 220,000,000.00 | 23,060,000,000.00 | 4,050,000,000.00 | 16,690,000,000.00 | 0.00 | 0.00 | 80,000,000.00 | 16,610,000,000.00 | 147,440,000,000.00 | 94,720,000,000.00 | 440,000,000.00 | 0.00 | 5,760,000,000.00 | 0.00 | 980,000,000.00 | 980,000,000.00 | 51,770,000,000.00 | 48,400,000,000.00 | 3,370,000,000.00 | 34,550,000,000.00 | 0.00 | 34,550,000,000.00 | 2,630,000,000.00 | 31,920,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 52,720,000,000.00 | 3,550,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22,180,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30,000,000.00 | 0.00 | 17,520,000,000.00 | 0.00 | 0.00 | 9,440,000,000.00 | 4,060,000,000.00 | 5,380,000,000.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 338,445,440.00 | 338,445,440.00 | 47,887,700,000.00 | 53,685,600,000.00 | 7,710,600,000.00 | 114,953,700,000.00 | -1,335,800,000.00 | 7,710,600,000.00 | 712,600,000.00 | 61,980,700,000.00 | 86,942,900,000.00 | 61,980,700,000.00 | 0.00 | 61,980,700,000.00 | 60,290,000,000.00 | 33,031,900,000.00 | 1,071,400,000.00 | 1,692,300,000.00 | 1,692,300,000.00 | 88,137,800,000.00 | 33,664,800,000.00 | 20,000,000.00 | 91,100,000.00 | 0.00 | 14,600,000.00 | 4,019,400,000.00 | 25,491,500,000.00 | 529,300,000.00 | 24,962,200,000.00 | 3,930,600,000.00 | 54,473,000,000.00 | 1,030,000,000.00 | 28,194,100,000.00 | 183,300,000.00 | 28,010,800,000.00 | 3,937,100,000.00 | 20,627,200,000.00 | 3,478,100,000.00 | 48,000,000.00 | 313,100,000.00 | 16,788,000,000.00 | 150,118,500,000.00 | 96,981,300,000.00 | 220,000,000.00 | 427,400,000.00 | 5,436,700,000.00 | 0.00 | 711,100,000.00 | 711,100,000.00 | 54,270,100,000.00 | 50,895,100,000.00 | 3,375,000,000.00 | 34,598,400,000.00 | -18,203,900,000.00 | 52,802,300,000.00 | 6,882,400,000.00 | 2,455,500,000.00 | 23,543,900,000.00 | 12,322,200,000.00 | 7,598,300,000.00 | 0.00 | 53,137,200,000.00 | 3,030,000,000.00 | 0.00 | 0.00 | 48,000,000.00 | 1,265,600,000.00 | 22,296,400,000.00 | 572,600,000.00 | 13,034,200,000.00 | 1,164,700,000.00 | 7,524,900,000.00 | 1,819,100,000.00 | 1,042,400,000.00 | 19,438,200,000.00 | -108,500,000.00 | 19,546,700,000.00 | 7,227,500,000.00 | 2,142,200,000.00 | 5,085,300,000.00 | 379,800,000.00 | 4,705,500,000.00 |
| 2023-03-31T00:00:00 | annual | 338,445,440.00 | 338,445,440.00 | 47,887,700,000.00 | 53,685,600,000.00 | 7,710,600,000.00 | 114,953,700,000.00 | -1,335,800,000.00 | 7,710,600,000.00 | 712,600,000.00 | 61,980,700,000.00 | 86,942,900,000.00 | 61,980,700,000.00 | 0.00 | 61,980,700,000.00 | 60,290,000,000.00 | 33,031,900,000.00 | 1,071,400,000.00 | 1,692,300,000.00 | 1,692,300,000.00 | 88,137,800,000.00 | 33,664,800,000.00 | 20,000,000.00 | 91,100,000.00 | 0.00 | 14,600,000.00 | 4,019,400,000.00 | 25,491,500,000.00 | 529,300,000.00 | 24,962,200,000.00 | 3,930,600,000.00 | 54,473,000,000.00 | 1,030,000,000.00 | 28,194,100,000.00 | 183,300,000.00 | 28,010,800,000.00 | 3,937,100,000.00 | 20,627,200,000.00 | 3,478,100,000.00 | 48,000,000.00 | 313,100,000.00 | 16,788,000,000.00 | 150,118,500,000.00 | 96,981,300,000.00 | 220,000,000.00 | 427,400,000.00 | 5,436,700,000.00 | 0.00 | 711,100,000.00 | 711,100,000.00 | 54,270,100,000.00 | 50,895,100,000.00 | 3,375,000,000.00 | 34,598,400,000.00 | -18,203,900,000.00 | 52,802,300,000.00 | 6,882,400,000.00 | 2,455,500,000.00 | 23,543,900,000.00 | 12,322,200,000.00 | 7,598,300,000.00 | 0.00 | 53,137,200,000.00 | 3,030,000,000.00 | 0.00 | 0.00 | 48,000,000.00 | 1,265,600,000.00 | 22,296,400,000.00 | 572,600,000.00 | 13,034,200,000.00 | 1,164,700,000.00 | 7,524,900,000.00 | 1,819,100,000.00 | 1,042,400,000.00 | 19,438,200,000.00 | -108,500,000.00 | 19,546,700,000.00 | 7,227,500,000.00 | 2,142,200,000.00 | 5,085,300,000.00 | 379,800,000.00 | 4,705,500,000.00 |
| 2022-03-31T00:00:00 | annual | 338,445,440.00 | 338,445,440.00 | 36,197,000,000.00 | 40,696,500,000.00 | 21,474,100,000.00 | 99,710,500,000.00 | 7,499,000,000.00 | 21,474,100,000.00 | 515,500,000.00 | 59,529,500,000.00 | 80,761,700,000.00 | 59,529,500,000.00 | 0.00 | 59,529,500,000.00 | 58,680,000,000.00 | 29,166,800,000.00 | 1,472,000,000.00 | 846,200,000.00 | 846,200,000.00 | 71,468,900,000.00 | 27,318,000,000.00 | 40,000,000.00 | 0.00 | 24,600,000.00 | 19,600,000.00 | 1,935,600,000.00 | 21,600,400,000.00 | 368,200,000.00 | 21,232,200,000.00 | 3,687,400,000.00 | 44,150,900,000.00 | 990,000,000.00 | 19,096,100,000.00 | 147,300,000.00 | 18,948,800,000.00 | 4,110,300,000.00 | 19,977,200,000.00 | 2,773,600,000.00 | 44,400,000.00 | 414,800,000.00 | 16,744,400,000.00 | 130,998,400,000.00 | 79,348,500,000.00 | 260,000,000.00 | 425,900,000.00 | 4,936,500,000.00 | 246,000,000.00 | 679,200,000.00 | 679,200,000.00 | 38,055,400,000.00 | 35,460,600,000.00 | 2,594,800,000.00 | 32,469,300,000.00 | -19,196,400,000.00 | 51,665,700,000.00 | 5,443,400,000.00 | 2,551,400,000.00 | 23,359,900,000.00 | 12,392,600,000.00 | 7,918,400,000.00 | 0.00 | 51,649,900,000.00 | 3,120,000,000.00 | 855,900,000.00 | 0.00 | 44,400,000.00 | 1,159,800,000.00 | 24,623,200,000.00 | 576,200,000.00 | 13,858,700,000.00 | 1,775,900,000.00 | 8,412,400,000.00 | 1,971,800,000.00 | 840,500,000.00 | 16,324,800,000.00 | -77,300,000.00 | 16,402,100,000.00 | 5,829,500,000.00 | 1,845,500,000.00 | 3,984,000,000.00 | 228,100,000.00 | 3,755,900,000.00 |
| 2021-03-31T00:00:00 | annual | 338,445,440.00 | 338,445,440.00 | 42,529,000,000.00 | 48,741,300,000.00 | 15,104,000,000.00 | 106,626,300,000.00 | 6,298,800,000.00 | 15,104,000,000.00 | 486,700,000.00 | 58,371,700,000.00 | 87,782,400,000.00 | 58,371,700,000.00 | 0.00 | 58,371,700,000.00 | 0.00 | 28,064,700,000.00 | 2,204,100,000.00 | 846,200,000.00 | 846,200,000.00 | 82,374,800,000.00 | 33,458,600,000.00 | 50,000,000.00 | 600,000.00 | 63,500,000.00 | 33,000,000.00 | 0.00 | 29,632,700,000.00 | 222,000,000.00 | 29,410,700,000.00 | 3,696,200,000.00 | 48,916,200,000.00 | 1,280,000,000.00 | 19,108,600,000.00 | 264,700,000.00 | 18,843,900,000.00 | 4,310,600,000.00 | 24,481,100,000.00 | 3,227,700,000.00 | 45,400,000.00 | 539,900,000.00 | 20,668,100,000.00 | 140,746,500,000.00 | 85,531,500,000.00 | 240,000,000.00 | 389,300,000.00 | 4,216,600,000.00 | 108,000,000.00 | 681,200,000.00 | 681,200,000.00 | 43,267,700,000.00 | 39,855,400,000.00 | 3,412,300,000.00 | 36,272,400,000.00 | -14,688,000,000.00 | 50,960,400,000.00 | 7,439,000,000.00 | 2,194,400,000.00 | 21,585,800,000.00 | 10,706,700,000.00 | 9,034,500,000.00 | 0.00 | 55,215,000,000.00 | 4,510,000,000.00 | 943,500,000.00 | 0.00 | 45,400,000.00 | 1,151,300,000.00 | 26,812,000,000.00 | 586,500,000.00 | 14,570,000,000.00 | 1,803,200,000.00 | 9,852,300,000.00 | 2,422,700,000.00 | 1,226,300,000.00 | 15,233,700,000.00 | -180,300,000.00 | 15,414,000,000.00 | 7,380,100,000.00 | 1,654,500,000.00 | 5,725,600,000.00 | 149,300,000.00 | 5,576,300,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 69,900,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18,600,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: TORNTPHARM Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repayment Of Debt | Issuance Of Debt | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Effect Of Exchange Rate Changes | Changes In Cash | Financing Cash Flow | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Net Long Term Debt Issuance | Long Term Debt Payments | Long Term Debt Issuance | Investing Cash Flow | Interest Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net Business Purchase And Sale | Purchase Of Business | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Capital Expenditure Reported | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Provisionand Write Offof Assets | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Gain Loss On Investment Securities | Net Foreign Currency Exchange Gain Loss | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 28,333,000,000.00 | -12,360,100,000.00 | 0.00 | -4,327,800,000.00 | 8,351,400,000.00 | 0.00 | 5,085,300,000.00 | 80,700,000.00 | 3,185,400,000.00 | -27,796,400,000.00 | -3,709,600,000.00 | -10,153,400,000.00 | 0.00 | -13,694,400,000.00 | -1,334,300,000.00 | -12,360,100,000.00 | -12,360,100,000.00 | 0.00 | -1,679,000,000.00 | 131,200,000.00 | 1,181,000,000.00 | 1,181,000,000.00 | 0.00 | 0.00 | 0.00 | -2,991,200,000.00 | 1,336,600,000.00 | -4,327,800,000.00 | 0.00 | 32,660,800,000.00 | -4,981,000,000.00 | 4,180,800,000.00 | -175,800,000.00 | 4,135,500,000.00 | -494,300,000.00 | 715,400,000.00 | 2,537,000,000.00 | 70,800,000.00 | 7,953,000,000.00 | 5,429,200,000.00 | 2,523,800,000.00 | -179,900,000.00 | -570,900,000.00 | 200,000.00 | 23,521,100,000.00 |
| 2023-03-31T00:00:00 | annual | 17,941,900,000.00 | -9,718,400,000.00 | 13,950,000,000.00 | -5,739,400,000.00 | 5,085,300,000.00 | 588,300,000.00 | 3,984,000,000.00 | 211,200,000.00 | 301,800,000.00 | 773,600,000.00 | -3,030,200,000.00 | -8,630,400,000.00 | 0.00 | 12,651,900,000.00 | 8,420,300,000.00 | 4,231,600,000.00 | -9,718,400,000.00 | 13,950,000,000.00 | -24,153,100,000.00 | 129,000,000.00 | -129,800,000.00 | 474,000,000.00 | -603,800,000.00 | -20,000,000,000.00 | -20,000,000,000.00 | -4,152,300,000.00 | 1,587,100,000.00 | -5,739,400,000.00 | 0.00 | 23,681,300,000.00 | -3,980,700,000.00 | -182,000,000.00 | 931,100,000.00 | -580,200,000.00 | 2,557,100,000.00 | -3,090,000,000.00 | 3,186,600,000.00 | 22,700,000.00 | 7,020,300,000.00 | 4,765,600,000.00 | 2,254,700,000.00 | -195,100,000.00 | -491,500,000.00 | -216,200,000.00 | 18,471,600,000.00 |
| 2022-03-31T00:00:00 | annual | 16,004,200,000.00 | -10,329,800,000.00 | 0.00 | -2,025,700,000.00 | 3,984,000,000.00 | 0.00 | 5,725,600,000.00 | 5,300,000.00 | -1,746,900,000.00 | -17,810,500,000.00 | -2,577,200,000.00 | -6,768,900,000.00 | 0.00 | -8,143,400,000.00 | 2,186,400,000.00 | -10,329,800,000.00 | -10,329,800,000.00 | 0.00 | -1,966,300,000.00 | 72,400,000.00 | -80,900,000.00 | 267,000,000.00 | -347,900,000.00 | 0.00 | 0.00 | -1,957,800,000.00 | 67,900,000.00 | -2,025,700,000.00 | 0.00 | 18,029,900,000.00 | -4,210,200,000.00 | -3,518,500,000.00 | -653,000,000.00 | -3,923,700,000.00 | 2,188,800,000.00 | -1,130,600,000.00 | 7,326,100,000.00 | 9,000,000.00 | 6,619,300,000.00 | 4,157,000,000.00 | 2,462,300,000.00 | -101,400,000.00 | -364,000,000.00 | 8,200,000.00 | 12,259,100,000.00 |
| 2021-03-31T00:00:00 | annual | 16,702,000,000.00 | -14,379,000,000.00 | 8,950,000,000.00 | -3,351,500,000.00 | 5,725,600,000.00 | 0.00 | 6,618,200,000.00 | 56,000,000.00 | -948,600,000.00 | -16,507,900,000.00 | -3,560,500,000.00 | -3,384,500,000.00 | -3,380,000,000.00 | -9,218,300,000.00 | -3,789,300,000.00 | -5,429,000,000.00 | -14,379,000,000.00 | 8,950,000,000.00 | -4,494,200,000.00 | 52,500,000.00 | -1,206,500,000.00 | 428,000,000.00 | -1,634,500,000.00 | 0.00 | 0.00 | -3,340,200,000.00 | 11,300,000.00 | -3,351,500,000.00 | 0.00 | 20,053,500,000.00 | -1,755,000,000.00 | -3,382,500,000.00 | 0.00 | 1,295,200,000.00 | -5,329,800,000.00 | 652,100,000.00 | 3,478,700,000.00 | 144,200,000.00 | 6,573,100,000.00 | 4,206,000,000.00 | 2,367,100,000.00 | -155,800,000.00 | -129,600,000.00 | 13,000,000.00 | 15,262,600,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7,190,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4,067,800,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: TORNTPHARM Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Minority Interests | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Impairment Of Capital Assets | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Research And Development | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 27.62 | 0.00 | 3,406.66 | 93.38 | 93.38 | 1,656.38 | 795.30 | 2,787.73 | 3,500.04 | 2,704.74 | -342.08 | 352.63 | 11.48 | 1,590.62 | 1,656.38 | 7,989.96 | 33.84 | 33.84 | 0.00 | 0.00 | 1,656.38 | 1,656.38 | 0.00 | 1,656.38 | 0.00 | 1,656.38 | 1,656.38 | 695.73 | 2,352.11 | 32.37 | 75.39 | -88.36 | 12.97 | -342.08 | 0.93 | 352.63 | 11.48 | 2,572.35 | 5,202.23 | 563.02 | 795.30 | 542.92 | 252.38 | 24.73 | 1,901.96 | 1,129.68 | 772.28 | 7,774.58 | 2,787.73 | 10,562.31 | 10,562.31 |
| 2023-03-31T00:00:00 | annual | 11.92 | 0.00 | 2,844.86 | 36.57 | 36.57 | 1,245.23 | 702.03 | 2,827.69 | 2,881.43 | 2,179.40 | -318.66 | 332.24 | 14.78 | 1,220.58 | 1,245.23 | 7,323.67 | 33.84 | 33.84 | 0.00 | 0.00 | 1,245.23 | 1,245.23 | 0.00 | 1,245.23 | 0.00 | 1,245.23 | 1,245.23 | 601.93 | 1,847.16 | 7.31 | 17.06 | -21.62 | 4.56 | -318.66 | 1.20 | 332.24 | 14.78 | 2,140.02 | 4,495.98 | 513.31 | 702.03 | 476.56 | 225.47 | 31.27 | 1,640.75 | 1,026.99 | 613.76 | 6,636.00 | 2,827.69 | 9,463.69 | 9,463.69 |
| 2022-03-31T00:00:00 | annual | -173.77 | 0.00 | 2,615.56 | -474.79 | -474.79 | 777.18 | 661.93 | 2,537.47 | 2,140.77 | 1,478.84 | -247.91 | 252.93 | 7.15 | 1,078.20 | 777.18 | 6,649.46 | 33.84 | 33.84 | 0.00 | 0.00 | 777.18 | 777.18 | 0.00 | 777.18 | 0.00 | 777.18 | 777.18 | 448.73 | 1,225.91 | 9.73 | -484.93 | 45.68 | 439.25 | -247.91 | 2.13 | 252.93 | 7.15 | 1,769.34 | 4,111.99 | 444.92 | 661.93 | 415.70 | 246.23 | 38.65 | 1,439.79 | 884.91 | 554.88 | 5,881.33 | 2,537.47 | 8,418.80 | 8,418.80 |
| 2021-03-31T00:00:00 | annual | 2.71 | 0.00 | 2,519.29 | 15.10 | 15.10 | 1,251.88 | 657.31 | 2,235.30 | 2,534.39 | 1,877.08 | -347.87 | 350.82 | 5.07 | 1,239.49 | 1,251.88 | 6,063.46 | 33.84 | 33.84 | 0.00 | 0.00 | 1,251.88 | 1,251.88 | 0.00 | 1,251.88 | 0.00 | 1,251.88 | 1,251.88 | 274.38 | 1,526.26 | 4.29 | -0.48 | 0.00 | 0.48 | -347.87 | 2.12 | 350.82 | 5.07 | 1,822.77 | 3,828.16 | 435.16 | 657.31 | 420.60 | 236.71 | 25.18 | 1,308.29 | 742.63 | 565.66 | 5,650.93 | 2,235.30 | 7,886.23 | 7,886.23 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
7/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
53.27
P/E
64.644264
P/B
15.548412
Dividend Yield
0.81%
Market Cap
116,546.92 Cr.
Face Value
221.476
Book Value
221.476
ROE
16.06%
EBITDA Growth
3,550.90 Cr.
Debt/Equity
41.658
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of torntpharm?
The market capitalization of Torrent Pharmaceuticals Limited is ₹116,547 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Torrent Pharmaceuticals Limited?
The PE and PB ratios of Torrent Pharmaceuticals Limited are Not Available and 15.548412 respectively as of 05 Feb 2025.
What is the 52 Week High of Torrent Pharmaceuticals Limited?
The 52-week high of Torrent Pharmaceuticals Limited is ₹3590.7 as of 05 Feb 2025.
What is the 52 Week Low of Torrent Pharmaceuticals Limited?
The 52-week low of Torrent Pharmaceuticals Limited is ₹2222.5 as of 05 Feb 2025.
What are the earnings per share (EPS) for Torrent Pharmaceuticals Limited?
The Earnings Per Share (EPS) of Torrent Pharmaceuticals Limited is ₹53.27 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Torrent Pharmaceuticals Limited?
The Return on Equity (ROE) of Torrent Pharmaceuticals Limited is 16.06% as per the most recent financial year data. Explore more on Fincept.